Triomics Secures $22 Million to Expand AI Solutions for Cancer Care Centres

Triomics, a healthcare technology startup developing AI-powered tools for oncology teams, has secured $22 million in Series B funding to accelerate growth of its platform, which automates complex clinical and administrative workflows in cancer care.

The funding round was led by Battery Ventures, with continued support from existing investors including Nexus Venture Partners, Lightspeed, Y Combinator, and several others.

Advances in cancer treatment are helping patients live longer than ever before, but that progress has also created a growing challenge for healthcare providers. Oncology patients often accumulate extensive medical histories spanning several years, resulting in records that can be difficult and time-consuming for clinicians and staff to review.

These records frequently include physician notes, pathology reports, imaging results, laboratory data, and even scanned documents such as faxes. According to Triomics co-founder Sarim Khan, some patient files contain thousands of pages of information that must be reviewed and interpreted before treatment decisions can be made.

Founded in 2021, Triomics previously raised a $15 million Series A round in 2024. The company initially focused on helping oncologists identify and match patients with appropriate clinical trials. As large language model technology advanced, the startup expanded its capabilities to address additional challenges faced by cancer care providers.

Over the past two years, Triomics has introduced AI-generated patient summaries that help clinicians prepare for appointments more efficiently. The platform highlights important clinical information directly within the systems healthcare professionals already use, reducing the need to switch between multiple applications during patient reviews.

By streamlining preparation, the platform allows oncologists to spend more time on patient care rather than on administrative tasks. This efficiency is especially valuable in oncology, where patient histories are often highly detailed, and healthcare staff regularly face heavy workloads and burnout.

In addition to supporting physicians, Triomics helps cancer centres automate the reporting of tumour-related data to government registries, a process often required by regulatory authorities and that can consume considerable administrative resources.

While general-purpose AI systems can generate summaries, Khan noted that leading institutions such as Memorial Sloan Kettering Cancer Centre and Yale Cancer Centre have adopted Triomics because its models are specifically trained on oncology-focused datasets. This specialisation enables the platform to understand the complexities of cancer care better and deliver more relevant clinical insights.

The company operates in a competitive market that includes AI-powered medical documentation providers such as Abridge and Microsoft’s Nuance. These platforms primarily focus on capturing and documenting physician-patient conversations, while Triomics focuses on analysing and organising cancer-related medical records and workflows.

Despite increasing competition across healthcare AI, Triomics has reported strong growth over the past year. According to Khan, the company expanded its enterprise customer base fourfold during that period, while annualised recurring revenue increased tenfold as more healthcare organisations adopted its oncology-focused solutions.

With fresh capital and growing demand from major cancer centres, Triomics plans to continue expanding its AI platform and further support healthcare providers seeking to reduce administrative burdens while improving patient care outcomes.